What’s Missing from Clinical Pathways in Cancer Care
Clinical pathways in the age of personalized cancer care may be excluding a key component: patient perspective.
Advocates Strategize on Pain Care Policy at GAfPA’s Malta Workshop
GAfPA’s workshop drew participants from across Europe who represented a multitude of backgrounds – all linked through their work with pain.
EU Group Calls for Greater Transparency in Labelling Biosimilars
EU regulators who want to encourage understanding and acceptance of biosimilar medicines might consider improving the drugs’ labels.
Research on Preventive Drugs Raises Hopes in the Migraine Community
For chronic migraine patients, the only thing better than making a headache stop is preventing it altogether. And new research suggests that patients may soon have new options for doing just that.
Patient Advocates Line Up Behind Federal Step Therapy Bill
A congressional effort to improve patients’ access to treatment is generating widespread enthusiasm in the advocacy community.
Cystic Fibrosis Group Defines Barriers to Treatment Access
Orphan drugs aren’t always reaching the patients who need them, and an advocacy group known as the Cystic Fibrosis Engagement Network has a few ideas as to why.
Drug Approval Signals New Era in Cancer Care
Is precision medicine gaining traction in the field of oncology? The Food and Drug Administration’s recent approval of the cancer drug pembrolizumab offers a hint.
High Out-of-Pocket Costs Threaten Access for Medicare Patients
Some Medicare beneficiaries pay 20 percent of their income in out-of-pocket medical expenses, a new study finds.
The New Face of Hepatitis C
Long considered an affliction of the baby boomer generation, hepatitis C now has spiked among a surprising new population: young people.
Drug Safety Data Underscores Need for Pharmacovigilance
One in every three new drugs triggers side effects discovered only after Food and Drug Administration approval, new data reveals. And that statistic begs a crucial question: How can we really ensure patients’ safety in an age of sophisticated medications and accelerated approval processes?
